Securing a debate for funding for Kadcyla

Home / News & Views / News / Securing a debate for funding for Kadcyla

18 January 2017

kadcyla Together with the support of dozens of MPs from all political parties, Siobhain has secured a three hour debate in the Chamber of the House of Commons to discuss 'Access to Kadcyla and other breast cancer drugs'. The debate will take place in the House of Commons Chamber, NEXT THURSDAY 26th January at around 2pm for three hours. 

If you have a personal story you would like to share relating to Kadcyla, or another secondary breast cancer drug that is under threat, or if you would like to come along to watch the debate in parliament, please email in at mcdonaghs@parliament.uk 

You can read the full motion below:

That this House notes the provisional decision not to provide the breast cancer drug Kadcyla for use in the NHS on 29 December 2016; and calls on the National Institute for Health and Care Excellence (NICE) and pharmaceutical company Roche to come together and re-assess this decision to ensure Kadcyla is kept
available for patients, and considers how access to both innovative new breast cancer drugs and off-patent drugs used for breast cancer, such as bisphosphonates, can be improved. 


Additional notes:

Due to changes in the Cancer Drugs Fund, the secondary breast cancer drug Kadcyla has recently been subject to another appraisal by the National Institute for Health and Care Excellence (NICE). It was provisionally rejected on 29 December 2016, which means that it could be withdrawn from new patients as early as June 2017, depending on the final decision that will be made in early 2017.

It is therefore very timely to have a debate to ensure that access to this drug is discussed in Parliament, as
well as the broader issue of access to both new innovative and off-patent drugs for breast cancer, which thousands of patients are dependent upon. This issue has a great deal of cross-party interest, particularly as breast cancer continues to be the most common cancer in the UK. 


back